49.26
0.38 (0.78%)
| Penutupan Terdahulu | 48.88 |
| Buka | 48.97 |
| Jumlah Dagangan | 26,238 |
| Purata Dagangan (3B) | 270,879 |
| Modal Pasaran | 920,170,048 |
| Harga / Pendapatan (P/E TTM) | 2.92 |
| Harga / Pendapatan (P/E Ke hadapan) | 9.29 |
| Harga / Jualan (P/S) | 3.45 |
| Harga / Buku (P/B) | 2.14 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Nov 2026 |
| Margin Keuntungan | 18.31% |
| Margin Operasi (TTM) | 23.95% |
| EPS Cair (TTM) | 2.09 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 80.60% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 1,845.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 544.23% |
| Nisbah Semasa (MRQ) | 2.20 |
| Aliran Tunai Operasi (OCF TTM) | 35.59 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 3.40 M |
| Pulangan Atas Aset (ROA TTM) | 18.15% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Rigel Pharmaceuticals, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 2.0 |
| Penilaian Relatif | 5.0 |
| Kesihatan Kewangan | 5.0 |
| AI Insight | NA |
| Purata | 2.00 |
|
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 2.66% |
| % Dimiliki oleh Institusi | 79.25% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
AI Analisis Teknikal
Buka tab Teknikal untuk menjana analisis terkini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |